

Annabel Alig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9786080/publications.pdf>

Version: 2024-02-01

9
papers

24
citations

2682572

2
h-index

2053705

5
g-index

10
all docs

10
docs citations

10
times ranked

16
citing authors

#	ARTICLE	IF	CITATIONS
1	Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy. <i>Cancers</i> , 2022, 14, 526.	3.7	1
2	Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial. <i>Frontiers in Oncology</i> , 2022, 12, 751453.	2.8	1
3	FIRE-9 — PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 359.	2.6	1
4	BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3576-3576.	1.6	2
5	Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3567-3567.	1.6	0
6	Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluorouracil/leucovorin plus panitumumab or 5-fluorouracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3587-3587.	1.6	0
7	Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 3571-3571.	1.6	0
8	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE —3). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	5.1	3
9	NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature. <i>European Journal of Cancer</i> , 2021, 153, 86-95.	2.8	16